Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials

doi:10.3390/cells10071629

CNU IR > Pharmacy and Science > Dept. of Cosmetic Science and institute of cosmetic science > Periodical Articles > Item 310902800/34402

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34402

Title:	Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials
Authors:	Lin, Yu-Hsuan Lin, Yueh-Chien Chen, Chien-Chin
Contributors:	Natl Sun Yat Sen Univ, Inst Biomed Sci Kaohsiung Vet Gen Hosp, Dept Otolaryngol Head & Neck Surg Natl Yang Ming Chiao Tung Univ, Sch Med Chung Shan Med Univ, Sch Med Natl Taiwan Univ, Dept Life Sci Harvard Med Sch, Boston Childrens Hosp, Dept Surg, Vasc Biol Program Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pathol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci
Keywords:	antagonist cancer clinical trial lysophosphatidic acid lysophosphatidic receptor therapy
Date:	2021
Issue Date:	2023-11-11 11:49:53 (UTC+8)
Publisher:	MDPI
Abstract:	Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled receptors, termed LPA receptors (LPAR1 to LPAR6). LPA signaling drives cell migration and proliferation, cytokine production, thrombosis, fibrosis, angiogenesis, and lymphangiogenesis. Since the expression and function of LPA receptors are critical for cellular effects, selective antagonists may represent a potential treatment for a broad range of illnesses, such as cardiovascular diseases, idiopathic pulmonary fibrosis, voiding dysfunctions, and various types of cancers. More new LPA receptor antagonists have shown their therapeutic potentials, although most are still in the preclinical trial stage. This review provided integrative information and summarized preclinical findings and recent clinical trials of different LPA receptor antagonists in cancer progression and resistance. Targeting LPA receptors can have potential applications in clinical patients with various diseases, including cancer.
Relation:	CELLS-BASEL, v.10, n.7, 1629
Appears in Collections:	[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

Files in This Item:

File	Description	Size	Format
cells10071629.pdf		1057Kb	Adobe PDF	74	View/Open
index.html		0Kb	HTML	287	View/Open

Loading...